Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study
AC Immune SAFebruary 11, 2021 GMT
Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease
ACI-35.030 was safe and well tolerated with no safety concerns observed. Results support plans to further develop the Alzheimer’s vaccine into Phase 2/3
LAUSANNE, Switzerland, Feb. 11, 2021 (GLOBE NEWSWIRE) AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD). ACI
AC Immune Reports Positive Interim Results from Novel Phase 1b/2a Alzheimer s Vaccine Trial Source:
Streetwise Reports (2/11/21) Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer s trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer s disease.
Switzerland-based clinical-stage biopharmaceutical firm AC Immune SA (ACIU:NASDAQ) today announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer s disease (AD).
The company highlighted that the ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels. Th